Search

Displaying results 1211 - 1220 of 1613 in total
  1. Drug

    Blonanserin

    go.drugbank.com/drugs/DB09223
    Investigational

    It offers improved tolerability as it lacks side effects such as extrapyramidal symptoms, excessive sedation, or hypotension.

  2. Drug

    S-8510

    go.drugbank.com/drugs/DB06504
    Experimental

    S-8510 / SB-737552 is a BZD inverse agonist investigated for the treatment of Alzheimer’s disease and mild to moderate senile dementia. It was being codeveloped by Shionogi and GlaxoSmithKline.

  3. Drug

    R1626

    go.drugbank.com/drugs/DB05060
    Experimental

    R1626 is one of a new class of hepatitis C therapies called polymerase inhibitors.

  4. Drug

    Linopristin

    go.drugbank.com/drugs/DB19296
    Experimental

    It is one part of the combination product NXL 103, along with [Virginiamycin M1].

  5. Drug

    5-deoxyflavanone

    go.drugbank.com/drugs/DB03601
    Experimental

    These are compounds containing a flavan-3-one moiety, whose structure is characterized by a 2-phenyl-3,4-dihydro-2H-1-benzopyran bearing a ketone at the carbon C3.

  6. Drug

    Venetoclax

    go.drugbank.com/drugs/DB11581
    ApprovedInvestigational

    A new indication was approved in 2018 for the treatment patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), with or without 17p deletion, who have received at least one

  7. Drug

    Repotrectinib

    go.drugbank.com/drugs/DB16826
    ApprovedInvestigational

    [A262056] ROS1 mutations are one of the defined oncogenic drives of NSCLC, and the solvent-front mutation ROS1 G2032R is responsible for 50 to 60% of [crizotinib]-resistant cases.

    Synonyms: (3R,6S,)-45-FLUORO-3,6-DIMETHYL-5-OXA-2,8-DIAZA-1(5,3)-PYRAZOLO(1,5-A)PYRIMIDINA-4(1,2)-BENZENANONAPHAN-9-ONE, (7S,13R)-11-Fluoro-7,13-Dimethyl-6,7,13,14-Tetrahydro-1,15-Ethenopyrazolo[4,3-F][1,4,8,10]Benzoxatriazacyclotridecin-4(5H)-One
  8. Drug

    Totrombopag

    go.drugbank.com/drugs/DB05930
    Investigational

    This drug is developed by GlaxoSmithKline and used to treat Thrombocytopenia.Thrombocytopenia (decreased platelet count) is a common side effect of many chemotherapies and can lead to uncontrolled bleeding

  9. Drug

    SQ-109

    go.drugbank.com/drugs/DB05186
    Investigational

    Currently in Phase I clinical trials, SQ-109 could replace one or more drugs in the current first-line TB drug regimen, simplify therapy, and shorten the TB treatment regimen.

  10. Drug

    INKP-102

    go.drugbank.com/drugs/DB05326
    Experimental

    INKP-102 is the next generation sodium phosphate tablet designed to aid bowl preparation before colonoscopy.